Drug · CHEMBL1908360
Trials813
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
1 to 20 of 813
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01589978 | PROMUS Element Plus US Post-Approval Study | Phase 4 | 2,681 | 2016-05-03 | everolimus | Its name | ClinicalTrials.gov |
| NCT01950819 | Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) | Phase 4 | 2,037 | 2019-01-30 | everolimus | Its name | ClinicalTrials.gov |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Phase 3 | 1,939 | 2023-12-20 | everolimus | Its name | ClinicalTrials.gov |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | Phase 3 | 1,545 | 2024-03-20 | everolimus | Its name | ClinicalTrials.gov |
| NCT00823212 | The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions | Phase 3 | 1,530 | 2012-01-27 | everolimus | Its name | ClinicalTrials.gov |
| NCT03468478 | Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation | Phase 4 | 1,209 | 2023-04-24 | everolimus | Its name | ClinicalTrials.gov |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Phase 3 | 1,069 | 2021-09-24 | everolimus | Its name | ClinicalTrials.gov |
| NCT00251004 | Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients | Phase 3 | 833 | 2011-05-10 | everolimus | Its name | ClinicalTrials.gov |
| NCT01114529 | Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients | Phase 3 | 828 | 2017-05-30 | everolimus | Its name | ClinicalTrials.gov |
| NCT01668784 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | Phase 3 | 821 | 2016-04-29 | everolimus | Its name | ClinicalTrials.gov |
| NCT00514514 | Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen | Phase 3 | 802 | 2017-01-18 | everolimus | Its name | ClinicalTrials.gov |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | Phase 3 | 755 | 2025-04-29 | everolimus | Its name | ClinicalTrials.gov |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | Phase 3 | 742 | 2017-07-12 | everolimus | Its name | ClinicalTrials.gov |
| NCT00863655 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole | Phase 3 | 724 | 2012-08-31 | everolimus | Its name | ClinicalTrials.gov |
| NCT00300274 | Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection | Phase 3 | 721 | 2012-08-16 | everolimus | Its name | ClinicalTrials.gov |
| NCT00622869 | Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients | Phase 3 | 719 | 2013-05-20 | everolimus | Its name | ClinicalTrials.gov |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | 719 | 2018-12-19 | everolimus | Its name | ClinicalTrials.gov |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | Phase 3 | 658 | 2017-07-18 | everolimus | Its name | ClinicalTrials.gov |
| NCT00879333 | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) | Phase 3 | 656 | 2015-04-06 | everolimus | Its name | ClinicalTrials.gov |
| NCT01025817 | Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients | Phase 3 | 613 | 2014-06-06 | everolimus | Its name | ClinicalTrials.gov |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908360/trials